WASHINGTON--(BUSINESS WIRE)--Ascenta Therapeutics Inc., today announced new clinical and preclinical data on its Phase 2 compound, AT-101, at the Sixth Annual Congress on Targeted Therapies in Cancer, held August 24th-26th in Washington, DC. Data presented were from the Phase 1 portion of an ongoing, open-label Phase 1/2 clinical study of AT-101 in combination with docetaxel and prednisone in men with hormone-refractory-prostate cancer (HRPC). The Phase 1 component of this multi-center study was designed to assess the safety and optimal dosing of the oral, pan-Bcl-2 inhibitor AT-101 when given in combination with docetaxel and prednisone, in preparation for Phase 2 study in a larger group of patients.
